Macrolides sales will expand through 2036, with azithromycin holding a 40.0% share in 2026 as the leading product segment. The market is expected to reach USD 42.0 billion in 2026 and USD 51.2 billion by 2036, creating an absolute dollar opportunity of USD 9.2 billion between 2026 and 2036.